Bayer Must Allow Cancer Generic In India, Court Rules

Law360, New York (March 12, 2012, 6:55 PM EDT) -- An Indian patent court has for the first time forced a pharmaceutical company to open up the generic market for a costly cancer drug, ordering Bayer AG to permit a cheaper version of its cancer treatment Nexavar, in a precedential ruling made public Monday.

The decision by the Indian Controller General of Patents, Designs and Trademarks allows Indian generic-drug maker Natco Pharma Ltd. to make and sell generic Nexavar, also called sorafenib, in exchange for a quarterly royalty to Bayer of 6 percent of net sales....
To view the full article, register now.